Lissa Wullaert

Mrs. Lissa Wullaert

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2023 in Cells
Verified
Journal Article
Open access
PDF file
LWLissa Wullaert
Lissa Wullaert
JRJan M. van Rees
Jan M. van Rees
JMJohn W.M. Martens
John W.M. Martens
HVHenk Verheul
Henk Verheul
DGDirk Jan Grünhagen
Dirk Jan Grünhagen
Cornelis VerhoefCornelis Verhoef
Cornelis Verhoef
Circulating tumour DNA (ctDNA) is a potential biomarker that could contribute to more judicious patient selection for personalised treatment. This review and meta-analysis gives an overview of the current knowledge in the literature investigating the value of ctDNA in patients with colorectal liver metastases (CRLM). A systematic search was conducted in electronic databases for studies published prior to the 26th of May 2023. Studies investigating the association between ctDNA and oncological outcomes in patients undergoing curative-intent local therapy for CRLM were included. Meta-analyses were performed to pool hazard ratios (HR) for the recurrence-free survival (RFS) and overall survival (OS). A total of eleven studies were included and nine were eligible for meta-analyses. Patients with detectable ctDNA after surgery experienced a significantly higher chance of recurrence (HR 3.12, 95% CI 2.27–4.28, p < 0.000010) and shorter OS (HR 5.04, 95% CI 2.53–10.04, p < 0.00001) compared to patients without detectable ctDNA. A similar association for recurrence was found in patients with detectable ctDNA after the completion of adjuvant therapy (HR 6.39, 95% CI 2.13–19.17, p < 0.0009). The meta-analyses revealed no association between detectable ctDNA before surgery and the RFS and OS. These meta-analyses demonstrate the strong association between detectable ctDNA after treatment and oncological outcomes in CRLM patients.

14 February 2023 in British Journal of Surgery
Verified
Journal Article
Open access
PDF file
LWLissa Wullaert
Lissa Wullaert
KVKelly R Voigt
Kelly R Voigt
CVCornelis Verhoef
Cornelis Verhoef
OHOlga Husson
Olga Husson
DGDirk Jan Grünhagen
Dirk Jan Grünhagen
Background: Previous trials found that more intensive postoperative surveillance schedules did not improve survival. Oncological follow-up also provides an opportunity to address psychological issues (for example anxiety, depression, and fear of recurrence). This systematic review assessed the impact of a less intensive surveillance strategy on health-related quality of life (HRQoL), emotional well-being, and patient satisfaction. Methods: A systematic search was conducted in PubMed/MEDLINE, Embase, Web of Science, Cochrane database, PsycINFO, and Google Scholar to identify studies comparing different follow-up strategies after oncological surgery and their effect on HRQoL and patient satisfaction, published before 4 May 2022. A meta-analysis was conducted on the most relevant European Organisation for Research and Treatment of Cancer QLQ-C30 and Hospital Anxiety and Depression Scale subscales. Results: Thirty-five studies were identified, focusing on melanoma (4), colorectal (10), breast (7), prostate (4), upper gastrointestinal (4), gynaecological (3), lung (2), and head and neck (1) cancers. Twenty-two studies were considered to have a low risk of bias, of which 14 showed no significant difference in HRQoL between follow-up approaches. Five studies with a low risk of bias showed improved HRQoL or emotional well-being with a less intensive follow-up approach and three with an intensive approach. Meta-analysis of HRQoL outcomes revealed no negative effects for patients receiving less intensive follow-up. Conclusion: Low-intensity follow-up does not diminish HRQoL, emotional well-being, or patient satisfaction.

30 January 2023 in Frontiers in Oncology
Verified
Journal Article
Open access
JRJan M. van Rees
Jan M. van Rees
LWLissa Wullaert
Lissa Wullaert
AGAlexander A. J. Grüter
Alexander A. J. Grüter
YDYassmina Derraze
Yassmina Derraze
PTPieter Tanis
Pieter Tanis
CVCornelis Verhoef
Cornelis Verhoef
Background: Circulating tumour DNA (ctDNA) has been established as a promising (prognostic) biomarker with the potential to personalise treatment in cancer patients. The objective of this systematic review is to provide an overview of the current literature and the future perspectives of ctDNA in non-metastatic rectal cancer.Methods: A comprehensive search for studies published prior to the 4th of October 2022 was conducted in Embase, Medline, Cochrane, Google scholar, and Web of Science. Only peer-reviewed original articles and ongoing clinical trials investigating the association between ctDNA and oncological outcomes in non-metastatic rectal cancer patients were included. Meta-analyses were performed to pool hazard ratios (HR) for recurrence-free survival (RFS).Results: A total of 291 unique records were screened, of which 261 were original publications and 30 ongoing trials. Nineteen original publications were reviewed and discussed, of which seven provided sufficient data for meta-analyses on the association between the presence of post-treatment ctDNA and RFS. Results of the meta-analyses demonstrated that ctDNA analysis can be used to stratify patients into very high and low risk groups for recurrence, especially when detected after neoadjuvant treatment (HR for RFS: 9.3 [4.6 – 18.8]) and after surgery (HR for RFS: 15.5 [8.2 – 29.3]). Studies investigated different types of assays and used various techniques for the detection and quantification of ctDNA.Conclusions: This literature overview and meta-analyses provide evidence for the strong association between ctDNA and recurrent disease. Future research should focus on the feasibility of ctDNA-guided treatment and follow-up strategies in rectal cancer. A blueprint for agreed-upon timing, preprocessing, and assay techniques is needed to empower adaptation of ctDNA into daily practice.

17 May 2023 in British Journal of Surgery
Verified
Journal Article
Open access
PDF file
KVKelly R Voigt
Kelly R Voigt
LWLissa Wullaert
Lissa Wullaert
MGMichelle R de Graaff
Michelle R de Graaff
CVCornelis Verhoef
Cornelis Verhoef
DGDirk Jan Grünhagen
Dirk Jan Grünhagen
Textbook outcome is a multidimensional quality measurement, which comprises the desirable short-term outcomes after surgery. This composite measure is reached when a patient meets all predefined requirements, resulting in a broader reflection of quality of care than single outcome measures. This aids clinicians in daily practice, giving insight into the quality of the entire surgical pathway from surgery to postoperative outcomes. Textbook outcome also provides an opportunity to evaluate variation between hospitals in a more objective manner, as it provides higher event rates and more power to detect differences than single outcomes.

12 August 2025 in eClinicalMedicine
Verified
Journal Article
Open access
LWLissa Wullaert
Lissa Wullaert
MJMaurice P.H.M. Jansen
Maurice P.H.M. Jansen
JKJaco Kraan
Jaco Kraan
YMYannick M. Meyer
Yannick M. Meyer
KVKelly Voigt
Kelly Voigt
NANinos Ayez
Ninos Ayez
Recurrence risk after curative surgery for colorectal liver metastases (CRLM) remains high, underlining the need to identify prognostic markers enabling more individualised treatment approaches. In the MIRACLE, a prospective, observational biomarker study, a total of 188 patients with isolated, resectable CRLM without (neo)adjuvant chemotherapy were included between October 2015 and December 2021. Blood samples were collected before surgery (baseline) and three weeks after surgery. The primary objective was to assess the potential association between postoperative circulating tumour DNA (ctDNA) detection and recurrence of disease for patients with resectable CRLM within one year after resection. The secondary objective was the association between recurrence of disease within one year and detection of circulating tumour cells (CTCs). Baseline ctDNA was measured by next generation sequencing using a targeted panel (Oncomine Colon cell-free DNA assay) and postoperatively by digital PCR on genetic variants found preoperatively with the Oncomine panel. CTCs were enumerated using the FDA-approved CellSearch system. ctDNA was detected in 117/187 patients (63%) at baseline, and 28/104 evaluable patients (27%) still had detectable ctDNA postoperatively. CTC enumeration resulted in positivity for 37/183 patients (20%) at baseline and 14/158 patients (9%) postoperatively. No association was found between 1-year recurrence-free survival (RFS) and the presence of CTCs or ctDNA at baseline. In contrast, patients with postoperative undetectable ctDNA had a significantly improved 1-year RFS compared to patients with postoperative ctDNA (54% [95% CI 44%–67%] vs. 25% [95% CI 13%–47%], log-rank p = 0.0011). Similarly, patients with postoperative detectable CTCs had a significantly shorter 1-year RFS compared to patients without postoperative CTCs (15% [95% CI 4%–55%] vs. 53% [95% CI 45%–62%], log-rank p 0.0004). Also in multivariable analysis, detectable ctDNA and CTCs after surgery remained independently associated with a shorter 1-year RFS (HR 2.35; 95% CI 1.34–4.11; p = 0.0028 and HR 2.98; 95% CI 1.56–5.71; p = 0.0010, respectively). This is the first study conducted in patients with resectable CRLM without (neo)adjuvant chemotherapy, which demonstrates the impact of postoperative detectable circulating tumour load on 1-year RFS. Postoperative ctDNA and CTC detection both represent strong, independent predictors for a shorter RFS after local treatment, as opposed to preoperative detection. This work was supported by 10.13039/501100004622 KWF Kankerbestrijding (Dutch Cancer Society, EMCR 2014-6340).

6 December 2024 in European Journal of Surgical Oncology
Verified
Journal Article
Open access
ELElze Lockhorst
Elze Lockhorst
JBJeske R.E. Boeding
Jeske R.E. Boeding
LWLissa Wullaert
Lissa Wullaert
RBRobert R.J. Coebergh van Den Braak
Robert R.J. Coebergh van Den Braak
ARArjen M. Rijken
Arjen M. Rijken
JSJennifer M.J. Schreinemakers
Jennifer M.J. Schreinemakers
To retrospectively analyse the short- and long-term oncological, morbidity and mortality outcomes in patients diagnosed with acute right-sided obstructing colon cancer. Patients who underwent pre-optimisation prior to the oncological resection were compared to patients who did not undergo pre-optimisation. All consecutive patients with right-sided obstructing colon cancer, either with a high clinical suspicion or confirmed diagnosis by histological analysis, who underwent curative-intent treatment between March 2013 and December 2020 were included. Patients were divided into two groups: an optimised group and a non-optimised group. Preoperative optimisation included additional nutrition, physiotherapy, and, if needed, bowel decompression. Data about disease-free survival and mortality were collected up to three years after surgery. Sixty-two patients were included. Thirty patients underwent the optimisation protocol before postponed surgery, and 32 patients received emergency surgery, without optimisation (surgery performed with a median of 9.6 days versus 22 h after admission). The postoperative complication rate was significantly lower in the optimisation group (50 % vs 78 %, p = 0.033). No significant differences were found in the 90-day mortality rate (7 % vs 13 %, p = 0.672) and three-year overall survival rate (43 % vs 56 %, p = 0.49). After three years, sixteen (53 %) patients in the optimised group and twenty (63 %) in the non-optimised were deceased (p = 0.672). Postponing the surgery with preoperative optimisation in patients with obstructing right-sided colon cancer results in a significantly lower 90-day complication rate and suggests no negative effect on survival rates compared to an acute resection. Although, further research with a larger sample size is needed.